Use

Reserving nucleic acids on any specimen for which molecular analysis requiring DNA or RNA may be necessary at a future date, ensuring that adequate material for testing is available. It is frequently useful to obtain nucleic acids from clinical samples containing a hematopoietic neoplasm at the time of diagnosis so appropriate material is available for molecular analysis should subsequent testing be required. For example, when a diagnosis of acute myelogenous leukemia is made, there is a delay before karyotype information, which determines whether testing for molecular prognostic markers is necessary, is available. After this delay, the diagnostic sample is usually no longer available or the nucleic acid has degraded to such an extent that it is no longer adequate for testing. Thus, it is useful to obtain nucleic acids on such specimens promptly at diagnosis and retain it until it is known whether additional testing is necessary.